Most of the presentations at SABCS focus on the latest clinical and basic research results relating to breast cancer. By contrast, educational sessions are designed to inform and update those interested in a review on a particular topic. Although these sessions may include new specific research findings, their primary intent is to offer summaries of existing knowledge, and to provide background for some of the active areas which will be discussed in the rest of the meeting.

Basic Science 101

Moderator: Suzanne A.W. Fuqua, PhD

Baylor College of Medicine

Houston, TX

Signaling

Douglas Yee, MD

University of Minnesota

Minneapolis, MN

Nuclear receptors

Suzanne A.W. Fuqua, PhD

Baylor College of Medicine

Houston, TX

Genetics / genomics

Laura J. van 't Veer, PhD

University of California San Francisco

San Francisco, CA

Clinical 101

Moderator: Andrea Richardson, MD, PhD

Dana-Farber Cancer Institute

Boston, MA

Clinical trial end points

Elizabeth Garrett-Mayer, PhD

Medical University of South Carolina

Charleston, SC

Pathology

Jane Elizabeth Brock, MBBS, PhD

Brigham & Women's Hospital

Boston, MA

Management and therapy

Carey K. Anders, MD

University of North Carolina at Chapel Hill

Chapel Hill, NC

Metastatic Breast Cancer: An Update on Management and Supportive Care

Moderator: Mothaffar Rimawi, MD

Baylor College of Medicine

Houston, TX

Update on management of ER positive metastatic breast cancer 

Harold J. Burstein, MD, PhD

Dana-Farber Cancer Institute

Boston, MA

Update on management of triple negative metastatic breast cancer

Lisa A. Carey, MD

University of North Carolina

Chapel Hill, NC

Symptom management and quality of life in metastatic breast cancer

Polly Niravath, MD

Baylor College of Medicine

Houston, TX

Global Trends in Breast Cancer Incidence and Mortality

Moderator: Ismail Jatoi, MD, PhD, FACS

UT Health Science Center San Antonio

San Antonio, TX

Trends in breast cancer incidence and mortality in developing countries

Peggy Porter, MD

University of Washington

Seattle, WA

Global trends in breast cancer subtypes

William F. Anderson, MD, MPH

National Cancer Institute

Rockville, MD

Declines in breast cancer mortality in the industrialized countries: What is behind it?

Donald A. Berry, PhD

UT MD Anderson Cancer Center

Houston, TX

DNA Damage Response as a Target of Therapy

Moderator: Rong Li, PhD

UT Health Science Center San Antonio

San Antonio, TX

Targeting ATR and the replication stress response

David Cortez, PhD

Vanderbilt University School of Medicine

Nashville, TN

Assays for DNA repair

Andre Nussenzweig, PhD

National Institute of Health

Bethesda, MD

Targeted therapies

Geoffrey I. Shapiro, MD, PhD

Dana-Farber Cancer Institute

Boston, MA

Individualized Adjuvant Decision Making

Moderator: Peter M. Ravdin, MD, PhD

UT Health Science Center San Antonio

San Antonio, TX

Decision making: Impact of patient age

Hyman B. Muss, MD

University of North Carolina at Chapel Hill

Chapel Hill, NC

Impact of Co-morbidities

Alistair Ring, MRCP, MD

Brighton & Sussex Medical School

Brighton, UNITED KINGDOM

Integration of the tumor, treatment, and patient elements

Peter M. Ravdin, MD, PhD

UT Health Science Center San Antonio

San Antonio, TX

Inflammatory Breast Cancer: Diagnosis, Treatment and Biology

Moderator: Wendy A. Woodward, MD, PhD

UT MD Anderson Cancer Center

Houston, TX

Diagnostic challenges, epidemiology, and updates in the search for IBC signaling determinants

Sofia D. Merajver, MD, PhD

University of Michigan

Ann Arbor, MI

Multidisciplinary management and evolving therapies

Massimo Cristofanilli, MD

Thomas Jefferson University

Philadelphia, PA

Radiation therapy, stem cells, and the microenvironment

Wendy A. Woodward, MD, PhD

UT MD Anderson Cancer Center

Houston, TX

Management of Premalignant Disease & Breast Cancer Prevention

Moderator: Powel H. Brown, MD, PhD

UT MD Anderson Cancer Center

Houston, TX

Trials – who should get prevention?

Jack Cuzick, PhD

Queen Mary University of London

London, UNITED KINGDOM

Clinical prevention

Powel H. Brown, MD, PhD

UT MD Anderson Cancer Center

Houston, TX

Pathology/biology of early lesions

Stuart J. Schnitt, MD

Harvard Medical Faculty Physicians at

Beth Israel Deaconess Medical Center

Boston, MA

Predicting Tumor Response by Functional Imaging

Moderator: Douglas Yee, MD

University of Minnesota

Minneapolis, MN

Optical imaging to probe signal transduction pathways

David Piwnica-Worms, MD, PhD

Washington University

St Louis, MO

PET imaging as a functional predictive biomarker

David Mankoff, MD, PhD

University of Pennsylvania

Philadelphia, PA

MR imaging for neoadjuvant response prediction

Nola Hylton, PhD

University of California, San Francisco

San Francisco, CA

William L. McGuire Memorial Lecture

Monica Morrow, MD, FACS

Memorial Sloan-Kettering Cancer Center

New York, NY

AACR Distinguished Lectureship in Breast Cancer Research

Signatures of Mutational Processes in Human Cancer

Michael Stratton, FMEDSCI FRS

The Wellcome Trust Sanger Institute

Cambridge, UNITED KINGDOM

Susan G. Komen for the Cure Brinker Awards for Scientific Distinction Lectures

Adoptive T-cell Treatment

Moderator: Malcolm K. Brenner, MD, PhD

Baylor College of Medicine

Houston, TX

Richard A. Morgan, PhD

National Cancer Institute

Bethesda, MD 

Artificial Receptors and the Cellular Therapy of Cancer

Malcolm K. Brenner, MD, PhD

Baylor College of Medicine

Houston, TX

HER2+ Breast Cancer: Unresolved Challenges

Moderator: C. Kent Osborne, MD

Baylor College of Medicine

Houston, TX

Translational insights in HER2+ breast cancer

Carlos L. Arteaga, MD

Vanderbilt-Ingram Cancer Center

Nashville, TN

Clinical frontiers in HER2+ breast cancer

Eric P. Winer, MD

Dana-Farber Cancer Institute

Boston, MA

Moderator: C. Kent Osborne, MD

Baylor College of Medicine

Houston, TX

Basic

Lewis A. Chodosh, MD, PhD

University of Pennsylvania

Philadelphia, PA

Translational

Charles M. Perou, PhD

University of North Carolina at Chapel Hill

Chapel Hill, NC

Clinical – early breast cancer

Joseph A. Sparano, MD

Montefiore Medical Center-Weiler Division

Bronx, NY

Clinical – metastatic breast cancer

Stephen R D Johnston, MA, FRCP, PhD

The Royal Marsden NHS Foundation Trust

London, UNITED KINGDOM

Cancer Metabolism

Moderator: Carlos L. Arteaga, MD

Vanderbilt-Ingram Cancer Center

Nashville, TN

Adrian L. Harris, BSc, DPhil

Oxford University

Oxford, UNITED KINGDOM

Matthew Vander Heiden, MD, PhD

Massachusetts Institute of Technology

Cambridge, MA

New Frontiers in Migration and Metastasis - Exosome

Moderator: Xiang Zhang, PhD

Baylor College of Medicine

Houston, TX

David C. Lyden, MD, PhD

Weill Cornell Medical College

New York, NY

Jeff Wrana, PhD

Samuel Lunenfeld Research Institute
Mount Sinai Hospital

Toronto, CANADA

 

Therapeutic Implications of Cancer Stem Cells

Moderator: Jeffrey M. Rosen, PhD

Baylor College of Medicine

Houston, TX

John E. Dick, PhD

Ontario Cancer Institute

Toronto, CANADA

Max S. Wicha, MD

University of Michigan Comprehensive Cancer Center

Ann Arbor, MI

Management of the Axilla After Neoadjuvant Systemic Therapy

Moderator: Richard L. Crownover, MD, PhD

UT Health Science Center San Antonio

San Antonio, TX

Lisa A. Newman, MD, MPH, FACS

University of Michigan Comprehensive Cancer Center

Ann Arbor, MI

Barbara Fowble, MD, FACR, FASTRO

University of California San Francisco

San Francisco, CA

Moderator: Mothaffar Rimawi, MD

Baylor College of Medicine

Houston, TX

The session is open to early-career scientists, defined as graduate students, postdoctoral or clinical fellows, or medical students and residents, who are registered attendees of the 2013 SABCS. Space in the workshop is limited to 300 participants; registrations will be accepted on a first-come, first-served basis and is free of charge. Click here for registration form.

8:00 AM-7:00 PM

12:00 PM-7:00 PM

7:00 AM-5:15 PM

8:00 AM-7:00 PM

11:00 AM-5:00 PM

7:00 AM-5:15 PM

7:30 AM-7:00 PM

11:00 AM-5:00 PM

7:00 AM-5:15 PM

7:30 AM-7:00 PM

11:00 AM-5:00 PM

7:00 AM-9:00 AM

7:30 AM-11:00 AM